Jazz Pharmaceuticals Q4 2023 Adj EPS $5.02 Misses $5.18 Estimate, Sales $1.01B Beat $1.00B Estimate
Portfolio Pulse from Benzinga Newsdesk
Jazz Pharmaceuticals reported Q4 2023 adjusted EPS of $5.02, missing the $5.18 estimate, but sales of $1.01B exceeded the $1.00B estimate, marking a 4.10% increase from the previous year.
February 28, 2024 | 9:09 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Jazz Pharmaceuticals' Q4 2023 earnings missed EPS estimates but beat sales forecasts, showing a year-over-year sales increase.
Missing the EPS estimate could negatively impact investor sentiment, but beating sales forecasts and showing year-over-year growth may counterbalance this effect. The mixed results lead to a neutral short-term price direction expectation.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100